PHC Holdings (PHCCF) Fair Value & Analysis
Healthcare · US · Market cap $937M
PHC Holdings
PHCCF · US
Fair value as of: Jul 19, 2026
From 21 valuation models · updated 22 days ago
A solid business, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- A fairly wide model range ($5.52 to $12.84) leaves room in how you read the outcome.
Price vs Fair Value (3 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 19, 2026.
How to read this chart
39‑month range $5.52 – $10.00 · fair‑value band $5.52 – $12.84 · the $7.41 price screens below the $7.51 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 19, 2026.
Analysis
PHC Holdings (PHCCF) currently trades at $7.41, while our model-based Fair Value estimate is $7.51, implying the stock looks roughly 1.4% fairly valued today. The Quality Score stands at 56/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, PHC Holdings generated revenue of $364B at a net margin of 0.1%. Revenue grew 0.5% year over year. It earns a return on equity of 0.2%. Net debt stands at $216B. Fundamentals as of Jul 19, 2026
Our scenario range runs from $5.52 (bear case) to $12.84 (bull case); at $7.41, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 3% below its 52-week high and 32% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at 1%, PHCCF screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 21 models by family
Widest divergence: Multiples ($8.74) versus Earnings-Based ($1.66). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 19, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 54 · Market factors (momentum, volatility) 67
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
PHC Holdings Corporation, together with its subsidiaries, provides healthcare digital and precision technology solutions in Japan, Europe, North America, and internationally. The company operates in three segments: Diabetes Management; Healthcare Solutions; and Diagnostic and Life Sciences.
Full company description
PHC Holdings Corporation, together with its subsidiaries, provides healthcare digital and precision technology solutions in Japan, Europe, North America, and internationally. The company operates in three segments: Diabetes Management; Healthcare Solutions; and Diagnostic and Life Sciences. It offers precision anatomical pathology for cancer, including tissue processors, digital pathology, and histology consumables; cell growth and preservation, such as CFC-free ultra-low temperature freezers, CO2 incubators, and live cell metabolic analyzer and cell expansion bioreactor system; and diagnostic testing comprising clinical testing, diagnostic reagents, and digital diabetes management solutions. The company also provides patient record and billing solutions, which include electronic medical record systems and receipt systems, systems for pharmacies, and wellness and prevention; diabetes management technology, such as blood and continuous glucose monitoring systems; and medical device and drug delivery comprising contract development and manufacturing services, drug delivery systems, and digital health. It serves patients, healthcare professionals, and researchers. The company was formerly known as Panasonic Healthcare Holdings Co., Ltd. and changed its name to PHC Holdings Corporation in April 2018. PHC Holdings Corporation was founded in 1948 and is headquartered in Chiyoda, Japan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
PHC Holdings reported revenue of $362B in FY2025 versus $306B in FY2021, a compound +4.3%/yr. Reported net income was $10.5B in FY2025, compounding −11.3%/yr from FY2021.
Watch PHCCF: get an alert when its fair value changes →
Peer Group
Medical Devices · 351 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare PHC Holdings with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is PHC Holdings (PHCCF) overvalued or undervalued?
What is the fair value of PHCCF?
What is the quality score of PHCCF?
What is the revenue of PHC Holdings (PHCCF)?
What is the net profit margin of PHCCF?
Does PHC Holdings pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track PHC Holdings and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.